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Lysosomal and phagocytic activity is
increased in astrocytes during
disease progression in the SOD1 G93A
mouse model of amyotrophic lateral
sclerosis
David J. Baker, Daniel J. Blackburn, Marcus Keatinge, Dilraj Sokhi, Paulius Viskaitis,
Paul R. Heath, Laura Ferraiuolo, Janine Kirby *† and Pamela J. Shaw †
Department of Neuroscience, Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK
Astrocytes are key players in the progression of amyotrophic lateral sclerosis (ALS).
Previously, gene expression profiling of astrocytes from the pre-symptomatic stage of the
SOD1G93A model of ALS has revealed reduced lactate metabolism and altered trophic
support. Here, we have performed microarray analysis of symptomatic and late-stage
disease astrocytes isolated by laser capturemicrodissection (LCM) from the lumbar spinal
cord of the SOD1G93A mouse to complete the picture of astrocyte behavior throughout
the disease course. Astrocytes at symptomatic and late-stage disease show a distinct
up-regulation of transcripts defining a reactive phenotype, such as those involved in the
lysosome and phagocytic pathways. Functional analysis of hexosaminidase B enzyme
activity in the spinal cord and of astrocyte phagocytic ability has demonstrated a
significant increase in lysosomal enzyme activity and phagocytic activity in SOD1G93A
vs. littermate controls, validating the findings of the microarray study. In addition to the
increased reactivity seen at both stages, astrocytes from late-stage disease showed
decreased expression of many transcripts involved in cholesterol homeostasis. Staining
for the master regulator of cholesterol synthesis, SREBP2, has revealed an increased
localization to the cytoplasm of astrocytes and motor neurons in late-stage SOD1G93A
spinal cord, indicating that down-regulation of transcripts may be due to an excess
of cholesterol in the CNS during late-stage disease possibly due to phagocytosis of
neuronal debris. Our data reveal that SOD1G93A astrocytes are characterized more by a
loss of supportive function than a toxic phenotype during ALS disease progression and
future studies should focus upon restorative therapies.
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INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder characterized by progressive
loss of motor neurons and resulting muscular weakness leading to death on average within 2–3
years of symptom onset. ALS occurs in approximately 2 per 100,000 population with incidence
enhanced by: increasing age; gender (1.6:1 male to female ratio); and genetic susceptibility. Five to
USA
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10% of cases of ALS are familial (fALS) and multiple causative
genes have been identified (Goodall et al., 2012). The most
common known genetic cause of ALS is a mutation in the
C9ORF72 gene (Dejesus-Hernandez et al., 2011; Renton et al.,
2011), implicated in approximately 7% of sporadic cases (sALS)
and 43% of fALS (Cooper-Knock et al., 2012). Mutations in
SOD1 (Cu/Zn superoxide dismutase (1) are the second most
common genetic cause of ALS, and account for 10–20% of
fALS (Cudkowicz et al., 1997). Transgenic mice expressing
mutant human SOD1 (mSOD1) are widely used as an animal
model of ALS, allowing for detailed study of motor neurons
and the surrounding glia during disease progression (Gurney
et al., 1994; Turner and Talbot, 2008). Using the SOD1G93A
model of ALS originally developed by Gurney et al. (1994) we
have developed the model on a homogeneous background
featuring highly consistent disease progression (Mead
et al., 2011), which allows analysis of discrete time-points in
disease.
Astrocytes play important roles in development, blood flow,
homeostasis, synaptic function, metabolism, and formation of
the blood brain barrier (Sofroniew and Vinters, 2010). In
ALS, astrocytes become activated in a process called reactive
astrogliosis, in which astrocytes become hypertrophic and
release increased levels of chemokines and cytokines (Blackburn
et al., 2009; Philips and Robberecht, 2011). Astrocytic protein
inclusions containing mSOD1 are an early feature of disease
in the mSOD1 mouse model (Bruijn et al., 1997). Selective
expression of mSOD1 in astrocytes alone failed to provoke
an ALS phenotype (Gong et al., 2000), but silencing mSOD1
expression in astrocytes significantly slowed disease progression
in the SOD1G37R mouse model (Yamanaka et al., 2008), without
affecting the level of astrogliosis. Studies using chimeric mice
have shown normal motor neurons develop features of ALS
pathology when surrounded by mSOD1-expressing glial cells
(Clement et al., 2003). In vitro mSOD1 astrocytes are selectively
toxic to motor neurons (Nagai et al., 2007; Bilsland et al.,
2008; Cassina et al., 2008; Díaz-Amarilla et al., 2011) and
this toxicity has been replicated in astrocytes derived from
human cases of sporadic and familial MND (Haidet-Phillips
et al., 2011; Re et al., 2014). In concert with these increased
toxic properties of astrocytes, ALS is characterized by a loss of
essential supportive behavior in these cells. Glutamate re-uptake,
a process in which astrocytes play a major part, is compromised
in the ALS spinal cord, motor cortex, and somatosensory
cortex (Rothstein et al., 1995). In vitro, the presence of mutant
SOD1 within astrocytes leads to altered GluR2 AMPA receptor
subunit expression in co-cultured neurons, increasing their
susceptibility to excitotoxic damage (Van Damme et al., 2007).
Mutant SOD1 is also suggested to render astrocytes vulnerable
to excitotoxic damage through activation of mGluR5 (Rossi
et al., 2008) which can be rescued by the anti-apoptotic Bcl-
XL leading to improved motor performance (Martorana et al.,
2011).
Gene expression profiling using microarray technology has
been used to delineate specific pathways that may serve
as therapeutic targets in ALS. Laser capture microdissected
(LCM) motor neurons from the SOD1G93A mouse model at
pre-symptomatic (∼60 day), symptomatic (∼90 day), and late-
stage (∼120 day) have been used previously to show the change
in motor neuron transcriptional behavior throughout the disease
course (Ferraiuolo et al., 2007). Microarray analysis of LCM
astrocytes, taken from the pre-symptomatic time-point revealed
dysregulated metabolic homeostasis, in particular a reduction in
lactate provision from astrocytes to motor neurons (Ferraiuolo
et al., 2011a). Due to the complexity of the disease process, a
transcriptomic approach is needed so that interactions between
the multiple disease mechanisms can be identified (Ferraiuolo
et al., 2011b). This approach can then be used to study the
specific changes that occur in astrocytes during ALS and how
these affect their interaction with motor neurons. The aim of
this study was to perform microarray analysis of laser-captured
SOD1G93A astrocytes from the symptomatic and late-stage
time-points to complement the previous work performed by
Ferraiuolo et al. (2011a) and to reveal the full extent of astrocytic
behavior during disease progression. The data show that an
activated phenotype becomes apparent at the symptomatic
stage which follows through to late-stage and is characterized
by an up-regulation of transcripts involved in lysosomal and
phagocytic pathways. We hypothesized that these pathways are
up-regulated at the functional level. To test this, we performed
enzymatic assays and in vitro experiments using fluorescently
labeled NSC34 cell debris to confirm an intrinsic lysosomal and
phagocytic up-regulation in SOD1G93A astrocytes. At the late-
stage, a dysregulation in transcripts involved in many steps of
cholesterol processing also occurs and immunohistochemistry
has confirmed an altered distribution of cholesterol processing
enzymes in late-stage lumbar spinal cord. In combination with
the pre-symptomatic data of Ferraiuolo et al. (2011a), these
findings provide a detailed map of astrocyte behavior throughout
disease and point to a loss of supportive function as the
overwhelming astrocyte phenotype that emerges during the
disease course.
MATERIALS AND METHODS
The SOD1G93A Mouse Model
The SOD1G93A mouse model, staining, LCM, and microarray
analysis were performed as in Ferraiuolo et al. (2011a). Mice used
were male SOD1G93A transgenic mice B6SJL-Tg (SOD1G93A)
1 Gur/J, which had been backcrossed onto C57Bl/6 J Ola/Hsd
(Harlan) for over 20 generations (Mead et al., 2011), and their
non-transgenic (NTg) littermates were used. Three mice were
used for disease and control groups at the symptomatic (90
days) and late-stage (120 days) time-points. All procedures
were performed according to UK Home Office regulations and
in accordance with guidelines specified by The University of
Sheffield Ethics Committee.
Rapid Immunohistochemistry (IHC) using
ALDH1L1
Rapid IHC staining of astrocytes, to allow rapid isolation of cells
and preservation of RNA quality, was performed as previously
described (Ferraiuolo et al., 2011a). Tissue sections (10µm) were
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stained with primary antibody (rabbit polyclonal anti-ALDH1L1,
Abcam, #ab 79727) at 1:50 dilution and secondary antibody and
ABC reagent were from the Vectastain Rabbit IgG kit (Vector
Labs # PK-6101).
Laser Capture of Astrocytes
A minimum of 1500 astrocytes per animal were captured by
LCM using the Arcturus Pixcell II microdissection instrument
(Applied Biosystems, Carlsbad, CA) using Arcturus Capsure
Macro LCM Caps (Applied Biosystems #LCM0211). RNA was
extracted from captured cells using the Arcturus Picopure RNA
Isolation kit (Applied Biosystems #12204-01) and tested for RNA
quantity using the Agilent Nanodrop spectrophotometer ND-
1000 (Agilent Technologies, Santa Clara, CA) and for quality
using the RNA 6000 PicoChip kit (Agilent # 5067-1513).
Microarray Data Analysis and Gene
Ontology Categorization
RNA was linearly amplified using the Two Rounds Amplification
kit (Affymetrix) as per manufacturer’s instructions. cRNA was
generated using the GeneChip Expression 3′ Amplification
Reagents for IVT labeling (Affymetrix). Fifteen micrograms
of cRNA for each of 3 × SOD1G93A and 3 × NTg mice
was fragmented (Genechip reagents, Affymetrix) and 12.5µg
hybridized onto Mouse Genome 430 2.0 Genechips (Affymetrix).
Prior to analysis probe sets were removed from the analysis
if all samples were called absent using the MAS5 algorithm
within Bioconductor (Gentleman et al., 2004). Initial GeneChip
analysis for determination of differentially expressed transcripts
was then performed using Genespring GX (Agilent) with
the Probe Logarithmic Intensity Error (PLIER) algorithm.
For Gene Ontology categorization, genes with p ≤ 0.05
and fold-change ≥2 were analyzed using the Database for
Annotation and Visualization (DAVID) in combination with
NetAffx Analysis Centre (www.affymetrix.com) and Genecards
V3 (www.genecards.org).
qPCR Validation
The amplified samples used in the microarray analysis were
diluted to 12.5 ng/µl and used for qPCR validation. Only selected
genes were validated via q-PCR due to the limited availability
of RNA from late stage animals following microarray analysis.
As a result some pathways were only validated by functional
tests. Genes were chosen based upon their presence in key
pathways of interest. Optimization of primer concentrations was
performed as described previously (Ferraiuolo et al., 2007). qPCR
was performed in 10µL reaction volumes using 5µL Brilliant
III Ultra Fast SYBR R© Green qPCR mastermix (Agilent). Primer
sequences, concentrations and the PCR programme used are
shown in Supplementary Table 1. To calculate relative expression
differences between SOD1G93A astrocytes and NTg controls the
2[-Delta Delta C(T)] method was used (Livak and Schmittgen,
2001). Gapdh was chosen as the housekeeping gene due to
a consistent expression level across all GeneChips and based
upon previous optimization at the presymptomatic time-point
(Ferraiuolo et al., 2011a).
Astrocyte Cell Culture
Primary astrocyte cultures were set up as previously described
(Ferraiuolo et al., 2011a). Cortices from 0 to 2 day old
SOD1G93A mice and their NTg littermates were used to
make separate cultures of astrocytes. The presence of the
transgene for each culture was ascertained using PCR for
each pup tail clip. Cells were cultured in DMEM containing
10% FBS until 100% confluence was reached, at which
time flasks were shaken overnight at 225 rpm at 37◦C
followed by mild trypsinisation (Saura et al., 2003) to separate
astrocytes from microglia. Astrocytes were defined as ≥95%
purity before use in experiments using a FACSCalibur flow
cytometer (BD) and antibodies against GLAST (Miltenyi
Biotech) and CD11b (Ebioscience) to check for microglial
presence.
β Hexosaminidase Activity Assay
Symptomatic and late-stage mice were euthanized via
intraperitoneal injection of pentobarbital and perfused with
PBS. Spinal cords were dissected, cut just above the lumbar
enlargement to give the “upper cord” and “lower cord,” and
rapidly frozen in liquid nitrogen. Sections of tissue (∼5 mg)
were dissected from the thoracic section of the upper cord
and the lumbar section of the lower cord on dry ice and
then homogenized using a glass tissue homogeniser (Jencons,
England). Protein concentration of homogenates was measured
using BCA assay (Sigma #B9643) and samples diluted to
1 mg/mL using distilled water. Five microliters of diluted
homogenate was added to 500µL McIlvaine citrate–phosphate
pH 4.5 buffer (MV4.5) and 100µL aliquots taken. All tubes
and substrate solution [4-Methylumbelliferyl N-acetyl-β-D-
glucosaminide (Sigma) at 1.1 mg/mL in MV4.5] were warmed
for 2min at 37◦C, before the substrate was added at timed
intervals in 100µL volumes to all tubes. All tubes were then
incubated at 37◦C for 10min and then stopping solution
(0.25M glycine buffer pH10.4) added at timed intervals. Sample
fluorescence was then read using a FLUOstar Omega platereader
(BMG Labtech) with excitation settings of 365 nm and emission
of 450 nm.
Astrocyte Phagocytosis Assay
Cell debris was created by placing complete medium containing
1:200Vybrant Dil (Life Technologies) onto the murine NSC34
motor neuronal cell line for 20min at 37◦C. Cells were washed
for 10min in fresh complete medium and were then placed
in serum-free DMEM for 48 h to induce cell death. Cells were
collected and counted and stored at −80◦C. Neonatal astrocytes
from SOD1G93A and NTg mice were seeded at a density of 4 ×
103 per well of a 384 well optical plate (Greiner Bio One) and
changed to serum-free medium (DMEM/F12 containing 1×N2)
24 h prior to exposure to cell debris. NSC34 debris was placed
onto astrocytes at a concentration of 125 cells/µL in serum-
free medium. Following a 48 h incubation at 37◦C, cultures were
washed 3 times with PBS and fixed with 4% PFA for 15min
at room temperature. As a negative control, cells were treated
with decreasing concentrations of Latrunculin A (10, 5, and
1µM), a commonly used phagocytosis inhibitor that forms a
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complex with actin filaments and inhibits actin polymerization
and elongation. One micromolar was the concentration that less
affected astrocyte viability and morphology and was, therefore,
used as a negative control for the phagocytosis assay. Cells were
treated overnight with 1µM Latrunculin A (Sigma), the day
after cells were washed and cell debris were applied onto the
cells as above. Astrocytes were stained with anti-GFAP antibody
(Abcam #ab7260) and nuclei were visualized using Hoescht
staining. The InCell 2000 (GE) was used for image capture of 9
fields per well (5 wells per sample) and subsequent analysis was
performed using InCell Developer Toolbox v.1.9 (GE) with an
analysis protocol that counted debris if ≥65% of debris-signal
overlapped with GFAP-signal. Confocal images of phagocytosis
were taken on a Leica SP5 confocal microscope using a x63/1.4
oil immersion objective lens. Z-stack images were taken at a
resolution of 512× 512 pixels at intervals of 0.12µm throughout
the depth of the cell of interest.
Immunohistochemistry for SREBP2
Sections of frozen spinal cord (10µm) were taken from
three symptomatic SOD1G93A mice and 3 age-matched NTg
controls. Staining was performed as per the manufacturer’s
protocol using the Vectastain Rabbit IgG kit as used for
Aldh1l1 staining. The primary antibody used was Ab282482
(AbCam) at 1:400 dilution in blocking solution. SREBP2
staining was visualized using diaminobenzidine and nuclei
were visualized using haemotoxylin. Microscopy was performed
using a Nikon Eclipse Ni microscope with a Nikon DS-
Ri1 camera using brightfield settings of 9.5ms exposure for
20X magnified images and 44ms exposure for 40X magnified
images.
Cholesterol Assay
Primary cortical astrocytes isolated from neonate SOD1G93A
mice and their NTg littermates were plated in a 96-well plate
at a density of 3 × 104 cells/well. Twenty-four hours post-
plating cells were either treated with U-18666A 1.25µM, a
cholesterol transport inhibitor, or medium was replaced. Forty-
eight hours later cells were fixed and cholesterol staining using
Filipin III was performed as per manufacturer’s instructions.
All wells were scanned and images collected using the InCell
2000 (GE). Image analysis was performed using ImageJ (http://
imagej.nih.gov/ij/). All images were treated as stacks and
adjusted for brightness, background and threshold using the
same parameters. Data on signal intensity and signal area
were collected using the function “Analyse Particles.” Three
independent cell preparations were analyzed in triplicate for each
condition.
Statistical Tests
All statistical analyses were performed in GraphPad Prism
v6.05 (Graphpad Software Inc.). qPCR data, phagocytosis and
cholesterol assay data was analyzed using an independent
samples t-test whilst lysosomal enzyme activity was analyzed
using One-way ANOVA with Tukey post-hoc test.
RESULTS
Gene Expression Profiling of Symptomatic
and Late-stage Astrocytes
The transcriptomics study performed here is the first to complete
an analysis of astrocytes from multiple stages of disease in the
SOD1G93A mouse model of ALS. There is an expected up-
regulation of many genes involved in astrocyte activation [e.g.,
glial fibrillary acidic protein (Gfap; 90d: ∼ +3, 120d: +10.48),
Cd44 (90d: +2.72; 120d: +5.56)] and inflammation signaling
a reactive astrocyte phenotype. In support of this, a profound
up-regulation of lysosomal genes is observed, which may reflect
a general increase in astrocyte reactivity already seen in ALS
and could be a response to increased phagocytic activity
of SOD1G93A astrocytes. Concurrently, SOD1G93A astrocytes
continue to decrease the expression of transcripts involved in
the support of neurons such as those involved in maintaining
homeostasis and neuronal support; steroid and cholesterol
biosynthesis, neurotransmitter receptors and potassium and
sodium ion channels important for sensing alterations in the
synaptic space.
All GeneChips from the symptomatic and late-stage time-
points were similar in terms of percentage present call (mean =
50.42% range = 36.27–57.81%) and average background signal
(mean= 33.41 range= 30.47–35.74) and GeneChips within each
time-point fell within the scale factor of three recommended
by Affymetrix. At the symptomatic time-point 276 transcripts
(corresponding to 321 probe sets due to multiple probe sets per
transcript) were differentially expressed with fold change≥2 and
p < 0.05 in SOD1G93A astrocytes compared to NTg controls with
117 transcripts (139 probe sets) showing decreased expression
and 159 transcripts (182 probe sets) increased expression. At
late-stage 1685 transcripts (2066 probe sets) were differentially
expressed with fold change ≥2 and p ≤ 0.05, with 1330
transcripts (1595 probe sets) showing decreased expression and
355 transcripts (471 probe sets) with increased expression. A list
of genes with FC≥ 2 and p < 0.05 for both symptomatic and late-
stage categorized by gene function is shown in Supplementary
Datasheet 1 [CEL files for each of the 12 GeneChips have
been uploaded to the Gene Expression Omnibus Repository
(GSE69166)]. PCR performed on glial cell markers before and
after picking showed the astrocyte marker GFAP to still be
present in LCM material, whilst levels of different cellular
markers in array material shows astrocytes to be a major
component of the picked material (Supplementary Figure 1).
Therefore, the RNA analyzed here is from amixed cell population
with a significant astrocytic component.
Enrichment analysis was performed for genes that were
differentially expressed at symptomatic and late-stage time-
points to assess genes involved from disease onset (Table 1
and Supplementary Datasheets 1–6). This showed symptomatic
and late-stage SOD1G93A astrocytes to be very similar in terms
of gene expression. The most enriched categories for up-
regulated transcripts by DAVID enrichment score consisted
of the lysosome, positive regulation of immune response and
positive regulation of phagocytosis, pointing to an increased
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TABLE 1 | Enrichment analysis of transcripts differentially expressed in
both the (A) symptomatic and (B) late-stage time-points in SOD1G93A
astrocytes vs. NTg controls (p ≤ 0.05, FC ≥ 2).
Term GO Count % Enrichment
score
A
UP-REGULATED TRANSCRIPTS
1 Positive regulation of phagocytosis 0050766 7 4.46 5.94
2 Lysosome 0005764 11 7 5.22
3 Phagocytosis 0006909 8 5.1 4.01
4 Regulation of B cell mediated immunity 0002712 6 3.82 4
5 IgG binding 0019864 4 2.55 3.32
6 T cell proliferation 0042098 5 3.18 2.85
7 Positive regulation of B-cell mediated
immunity
0002714 4 2.55 2.74
8 Regulation of type III hypersensitivity 0001803 3 1.91 2.55
9 Regulation of actin cytoskeleton
organization
0032956 5 3.18 2.39
10 Positive regulation of apoptosis 0043065 8 5.10 2.08
DOWN-REGULATED TRANSCRIPTS
1 Voltage-gated cation channel activity 0022843 8 6.84 5.08
2 Cation channel activity 0005261 9 7.69 4.47
3 Ion channel activity 0005216 10 8.55 4.44
4 Potassium ion binding 0030955 7 5.98 3.67
5 Cellular ion homeostasis 0006873 7 5.98 1.95
6 Regulation of neuron differentiation 0045664 4 3.42 1.43
7 Cellular metal ion homeostasis 0006875 4 3.42 1.4
8 Positive regulation of immune response 0050778 4 3.42 1.18
9 Metal ion binding 0046872 23 19.66 0.92
10 Skeletal muscle tissue development 0007519 3 2.56 0.87
B
UP-REGULATED TRANSCRIPTS
1 Lysosome 0005764 16 4.64 4.55
2 Complement activation, classical pathway 0006958 6 1.74 3.33
3 Positive regulation of phagocytosis 0050766 6 1.74 2.99
4 Positive regulation of cell migration 0030335 6 1.74 2.57
5 Positive regulation of immunoglobulin
mediated immune response
0002891 4 1.16 2.30
6 Negative regulation of protein kinase
activity
0006469 6 1.74 2.07
7 Protein maturation by peptide bond
cleavage
0051605 7 2.03 2.02
8 Positive regulation of type II
hypersensitivity
0002894 3 0.87 2.01
9 Regulation of phosphorylation 0042325 15 4.35 1.91
10 Positive regulation of adaptive immune
response
0002821 5 1.45 1.90
DOWN-REGULATED TRANSCRIPTS
1 Ion channel activity 0005216 58 4.36 9.14
2 Adenyl nucleotide binding 0030554 160 12.02 8.09
3 Modification-dependent macromolecule
catabolic process
0043632 66 4.96 5.81
4 Nucleotide biosynthetic process 0009165 28 2.1 4.15
(Continued)
TABLE 1 | Continued
Term GO Count % Enrichment
score
5 Hydrolase activity, acting on acid
anhydrides, catalyzing transmembrane
movement of substances
0016820 17 1.28 3.19
6 ATP metabolic process 0046034 16 1.2 2.56
7 ATP biosynthetic process 0006754 15 1.13 2.46
8 Chloride channel activity 0005254 11 0.83 1.88
9 Neurofilament cytoskeleton 0060053 5 0.38 1.71
10 Cyclase activity 0009975 6 0.45 1.66
Category names have been summarized from the most significant cluster annotation
terms. GO, gene ontology term code; Count, number of genes; %, proportion of total
gene list; Enrichment score, DAVID enrichment score (higher values are more significant).
reactivity of astrocytes beginning at symptom onset. Potassium
transport was down-regulated at the symptomatic stage which
developed into a more general disruption in ion homeostasis at
late-stage, which also featured dysregulation of ATP biosynthesis
genes. This may signify an increased inability of astrocytes from
symptomatic to late-stage disease to sense their environment.
Lysosomal Up-regulation Occurs at
Symptomatic Stage and Continues to
Late-stage Disease
To functionally validate the findings of the gene expression data,
we chose to investigate the increased reactivity of astrocytes
that is apparent at the symptomatic stage and continues to
late-stage disease. Due to the enrichment for lysosomal genes
at both time-points, we chose to investigate this group of
genes first. There is a clear up-regulation of lysosomal genes in
SOD1G93A astrocytes at both symptomatic and late-stage time-
points (Table 2). The genes involved include several lysosomal
digestive proteases: cathepsin D (Ctsd), cathepsin H (Ctsh),
cathepsin S (Ctss), cathepsin Z (CtsZ); two glycosidase subunits:
hexosamindase A (Hexa) and hexosaminidase B (Hexb); and two
minor lysosomal membrane proteins: solute carrier family 11
member 1 (Slc11a1) and lysosomal associated transmembrane
protein 5 (Laptm5). Out of five genes chosen for validation
by qPCR, all showed regulation in the same direction as the
microarrays and three genes (Hexa, Ctsd, and Ctss) showed a
statistically significant difference between disease and control
(Figure 1A). This indicated that several aspects of lysosomal
activity are increased in the SOD1G93A spinal cord as the disease
progresses. To assess whether the differential expression of
these genes translates to a functional difference in lysosomal
enzyme activity we assayed the activity of β-hexosaminidase
(β-hex) in the upper and lower spinal cord. β-hex is encoded
by the Hexa and Hexb transcripts (Mahuran, 1995). B-hex
activity was significantly increased compared to controls in
the upper cord and lower cord at the late-stage of disease
(Figure 1B). As in our previous work upon motor neurons
from different disease stages of the SOD1G93A mouse, no
differences were observed between NTg littermates and mice
overexpressing wild-type human SOD1 andNTg littermates were
Frontiers in Cellular Neuroscience | www.frontiersin.org 5 October 2015 | Volume 9 | Article 410
Baker et al. The changing astrocyte phenotype during ALS
TABLE 2 | Lysosomal genes differentially expressed with p ≤ 0.05 and
fold-change ≥2 in SOD1G93A astrocytes vs. NTg controls.
Gene Full name Affymetrix Symptomatic Late-stage
probeset ID FC FC
CD164 cd164 1416440_at −3.2
CD68 cd68 1449164_at +4.16 +3.74
Ctsb Cathepsin B 1444987_at +2.34
Ctsd Cathepsin D 1448118_a_at +2.32 +3.28
Ctsh Cathepsin H 1418365_at +2.4 +2.77
1443814_x_at +2.17 +3.25
Ctss Cathepsin S 1448591_at +2.53 +4.07
Ctsz Cathepsin Z 1417868_a_at +3.22 +3.62
1417869_s_at +2.91 +4.67
1417870_x_at +3.12 +3.21
Hexa Hexosaminidase A 1449024_a_at +2.26 +2.38
Hexb Hexosaminidase B 1460180_at +2.54 +2.96
Hgsnat Heparan-alpha-
glucosaminide
N-acetyltransferase
1436580_at +2.18
Laptm4b Lysosomal-associated
protein transmembrane
4B
1416148_at −2.92
Laptm5 Lysosomal-associated
transmembrane protein 5
1426025_s_at +2.52 +4.5
1459841_x_at +2.81 +6.45
1417721_s_at +3.13
1436905_x_at +6.45
Slc15a3 Solute carrier family 15,
member 3
1420697_at +3.18 +2.79
used for all further experiments to reduce the number of animals
used.
Enhanced Reactivity of SOD1G93A
Astrocytes is Demonstrated by Increased
Phagocytic Activity
Gene categories relating to the immune response are up-
regulated at both the symptomatic and late-stage time-points
in SOD1G93A astrocytes (Table 3). There is an up-regulation of
chemotactic genes, with seven genes in the KEGG chemokine
signaling pathway differentially expressed in symptomatic
SOD1G93A astrocytes (Table 3). Only two of these genes, Ccl6
and Cxcl10 are differentially expressed at late-stage. Ccl6 but not
Cxcl10 was validated by qPCR (Figure 2A). The complement
pathway, an innate immune mechanism for the destruction of
invading pathogens, is up-regulated at both disease stages, with
C1qb validated by qPCR as differentially expressed (Figure 2A).
The complement pathway consists of a cascade of protein
activation, centered around C1q, the three components of which
(C1qa, b, and c) are up-regulated at symptomatic and further
at late-stages in our microarray of astrocytes with C1q and
C4b showing the most highly significant differential expression
(p ≤ 0.0001) of all dysregulated genes at late stage disease. C1q
binds to antigen-antibody and stimulates phagocytic activity (van
Beek et al., 2003) and several other stimulants of phagocytosis
are also up-regulated such as Clec7a and Ptx3. Along with
these classic immune response transcripts, markers of astrocyte
FIGURE 1 | (A) qPCR upon symptomatic RNA of five lysosomal transcripts
differentially expressed on symptomatic and late-stage microarrays; n = 3 per
group. (B) Enzyme activity of Hexosaminidase B in the upper and lower spinal
cord of SOD1WT, SOD1G93A, and NTg controls (SOD1WT, 90d NTg, and 90d
SOD1G93A: n = 3, 120d NTg and 120d SOD1G93A: n = 4). Error bars =
S.E.M. *p ≤ 0.05, **p ≤ 0.01, ****p ≤ 0.0001 vs. age-matched NTg
control. #p ≤ 0.05, ####p ≤ 0.0001 vs. SOD1WT control.
reactivity were also up-regulated such as activating transcription
factor 3 (Atf3) and serpin peptidase inhibitor clade A member
3 (Serpina3n), which were both confirmed as differentially
expressed by qPCR (Figure 2A). We next investigated whether
the increased immuno-reactive phenotype of astrocytes led
to differences in phagocytic ability. Cortical astrocytes from
neonatal mice were used due to the difficulty of obtaining
a sufficient number of proliferating astrocytes from adult
spinal cord (data not shown). Astrocytes expressing SOD1G93A
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TABLE 3 | Genes involved in the phagocytic and immune response
categories that are differentially expressed in symptomatic and late-stage
SOD1G93A astrocytes vs. NTg controls (p ≤ 0.05, FC ≥ 2).
Gene Full name Affymetrix Symptomatic Late-stage
probeset ID FC FC
REGULATION OF PHAGOCYTOSIS
fcgr1 Fc receptor, IgG, high
affinity I
1417876_at +2.56
Fcer1g Fc receptor, IgE, high
affinity I, gamma
polypeptide
1418340_at +2.58 +3.00
Slc11a1 Solute carrier family 11
(proton-coupled divalent
metal ion transporters),
member 1
1420361_at +2.87 +3.20
Clec7a C-type lectin domain
family 7, member a
1420699_at +16.26 +11.38
Ptx3 Pentraxin related gene 1418666_at +2.04 +2.83
Fcgr2b Fc receptor, IgG, low
affinity IIb
1435477_s_at +2.35
Fcgr3 Fc receptor, IgG, low
affinity III
1448620_at +2.85 +4.00
COMPLEMENT CASCADE
Itgb2 Integrin beta 2 1450678_at +2.85
A2m Alpha-2-macroglobulin 1434719_at +3.28 +11.38
C1qa Complement component
1
1417381_at +3.97 +7.98
C1qb Complement component
1
1417063_at +3.4 +4.21
1434366_x_at +2.36 +8.6
1437726_x_at +2.25 +8.89
C1qc Complement component
1
1449401_at +3.91 +5.75
C3 Complement component
3
1423954_at +9.44
C3ar1 Complement component
3a receptor 1
1442082_at +2.37
C4b Complement component
4b
1418021_at +6.27 +28.67
Cd55 cd55 1418762_at −2.48
1443906_at −2.04
CHEMOKINE SIGNALING
Adcy7 Adenylate cylase 7 1450065_at +3.02
Ccl3 Chemokine (C-C motif)
ligand 3
1419561_at +9.01
Ccl4 Chemokine (C-C motif)
ligand 4
1421578_at +2.12
Ccl6 Chemokine (C-C motif)
ligand 6
1417266_at +4.42 +2.85
Ccl9 Chemokine (C-C motif)
ligand 9
1417936_at +2.05
Cxcl10 Chemokine (C-X-C motif)
ligand 10
1418930_at +3.54 +10.37
Dock2 Dedicator of cyto-kinesis 2 1422808_s_at +2.54
OTHER/REACTIVITY
Atf3 Activating transcription
factor 3
1449363_at +6.82 +4.23
Serpina3n Serine peptidase inhibitor,
clade A, member 3n
1419100_at +3.90 +8
phagocytosed significantly higher amounts of debris compared
with NTg controls [204.84% (SOD1G93A) vs. 100% (NTg),
S.E.M = 25.88 (SOD1G93A) vs. 12.62 (NTg), p = 0.0112] as
measured using the InCell 2000 (Figure 2B). The InCell system
was used for phagocytosis analysis due to the ability to run the
assay in a 384-well format and allow automated image analysis.
In order to check that debris had been engulfed and were not
simply stuck to the cell surface of astrocytes, confocal microscopy
was then used to confirm that debris were localized in the same
plane as the astrocyte marker GFAP (Figure 2C) adding to the
observation of prominent GFAP staining seen around engulfed
material during InCell analysis (Figure 2D). In addition, the use
of a phagocytic inhibitor, Latrunculin, abolished phagocytosis of
NSC34 cell debris (Supplementary Figure 2).
Cholesterol Processing Transcripts are
Dysregulated in Late-stage SOD1G93A
Astrocytes
Whilst analysing the symptomatic and late-stage datasets,
we noticed that there were a large number of differentially
expressed transcripts involved in cholesterol synthesis in late-
stage SOD1G93A astrocytes that had not been identified by
DAVID analysis (Table 4). When the late-stage gene list is
analyzed in isolation this category contains 38 transcripts
passing a fold-change ≥2, the majority of which (35 transcripts)
are down-regulated, with several genes representing key
components of the cholesterol synthesis pathway (Figure 3A).
Measurement of intracellular cholesterol levels in neonatal
SOD1G93A astrocytes after inhibiting cholesterol export showed
that transgenic astrocytes produce less than half the cholesterol
of NTg control astrocytes (Figure 3B). To investigate whether
cholesterol synthesis was affected in SOD1G93A spinal cord,
we performed staining for sterol regulatory binding protein 2
(SREBP2), a master regulator of cholesterol synthesis genes.
SREBP2 is a transcription factor which is processed and re-
located to the nucleus during low cholesterol conditions to up-
regulate cholesterol synthesis genes (Figure 3C). SREBP2 is also
involved in the transcription of the low density lipoprotein
receptor (LDLR) which is down-regulated at the transcript level
(-3.39) in late-stage SOD1G93A astrocytes. Srebp2 is not down-
regulated at the transcript level in either symptomatic or late-
stage astrocytes. However, in late-stage SOD1G93A spinal cord
we saw an increased staining for SREBP2 in cells with motor
neuron morphology and within processes that may belong to
astrocytes (arrowhead in Figure 3D). In contrast NTg spinal cord
contains no such astrocytic processes and negatively stained areas
with motor neuron morphology. Taken together, the increased
staining of SREBP2 in the cytoplasm of SOD1G93A motor
neurons may be an attempt by neurons to increase cholesterol
synthesis because of reduced astrocytic cholesterol provision.
Overlapping Gene Expression of
Pre-symptomatic, Symptomatic, and
Late-stage SOD1G93A Astrocytes
Pre-symptomatic SOD1G93A astrocytes have already undergone
gene expression profiling by Ferraiuolo et al. (2011a) which
enables a comparison of the gene lists generated at three
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FIGURE 2 | (A) qPCR upon symptomatic RNA of five transcripts differentially expressed in symptomatic and late-stage SOD1G93A astrocyte microarray data and
putatively involved in their immuno-reactive phenotype, including the chemokines Ccl6 and Cxcl10, the complement component C1qb, the stress response
transcription factor Atf3 and the serpin peptidase inhibitor Serpina3n; n = 3 per group. (B) SOD1G93A astrocytes phagocytose a significantly greater area of debris vs.
NTg control. Results expressed as a percentage of control (NTg = 100% ± S.E.M. 12.62, SOD1G93A = 204.84% ± S.E.M = 25.88). n = 3. (C) Confocal microscopy
reveals NSC34 debris (red) to be in the same plane as GFAP staining (green). Crosshairs indicate location of zy and zx view. Note colocalisation of debris and GFAP in
zx field. Both nuclei of astrocytes and nuclear debris of NSC34 cells are observed stained blue. (D) InCell image of GFAP+ astrocytes (green) phagocytosing NSC34
cell debris (red), nuclei are stained in blue. *p ≤ 0.05, **p ≤ 0.01. Error bars = S.E.M. Scale bars = 25µm.
time-points of the disease. The number of transcripts with
differential expression passing p ≤ 0.05 and FC ≥ 2 in
common between all three time-points was investigated using
a Venn diagram (Figure 4). There is high variability in the
number of transcripts differentially expressed at FC ≥ 2
between the three time-points, with the symptomatic stage
showing a lower number of transcripts (276) compared to
the pre-symptomatic (878) and late-stage (1685) GeneChips.
The highest proportion of genes shared is between the
symptomatic and late-stage time-points where 17% of up-
regulated and 4.5% of down-regulated transcripts are in common
(for full lists of shared genes see Supplementary Datasheet 6).
The separation also shows that there is a large amount of
transcriptional down-regulation at late-stage disease compared
to the other time-points which are more evenly split, as
previously seen in our microarray studies of the corresponding
time-points of SOD1G93A motor neurons (Ferraiuolo et al., 2007).
The overlap between the pre-symptomatic + late-stage and
symptomatic + late-stage time-points is more evenly matched
for down-regulated transcripts, whereas the overlap between
the pre-symptomatic and symptomatic time-points is again very
small. This reinforces the findings of our enrichment analyses
(Table 1) which featured many common categories between the
symptomatic and late-stage time-points.
DISCUSSION
Gene expression profiling of astrocytes from the SOD1G93A
transgenic mouse at symptomatic and late-stage disease time-
points and subsequent combination with the previous analysis
by Ferraiuolo et al. (2011a) at the pre-symptomatic stage has
allowed a picture of astrocyte behavior throughout the ALS
disease course in the murine model to be seen for the first
time (Figure 5). The pre-symptomatic time-point is highly
associated with an alteration of supportive function in SOD1G93A
astrocytes, such as the provision of lactate to motor neurons
and altered secretion of pro-nerve growth factor (ProNGF).
In the current study, we have identified an altered immune
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TABLE 4 | Transcripts involved in cholesterol homeostasis that are
differentially expressed in symptomatic and late-stage SOD1G93A
astrocytes vs. NTg controls (p ≤ 0.05, FC ≥ 2).
Gene Full name Affymetrix Symptomatic Late-stage
probeset ID FC FC
Abca5 ATP-binding cassette,
sub-family A (ABC1),
member 5
1434474_at −3.21
Abcb7 ATP-binding cassette,
sub-family B (MDR/TAP),
member 7
1435006_s_at −2.44
Abcc8 ATP-binding cassette,
sub-family C (CFTR/MRP),
member 8
1455765_a_at −2.06
Abcd2 ATP-binding cassette,
sub-family D (ALD), member
2
1456812_at −2.58
Acat2 Acetyl-Coenzyme A
acetyltransferase 2
1435630_s_at −2.33
Acsl4 Acyl-CoA synthetase
long-chain family member 4
1433531_at −2.35
Acsl6 Acyl-CoA synthetase
long-chain family member 6
1437031_at −2.59
Acss2 Acyl-CoA synthetase
short-chain family member 2
1422478_a_at −2.23
ApoE Apolipoprotein E 1432466_a_at +2.18 +5.23
Capn7 calpain 7 1423096_at −2.00
Ch25h Cholesterol 25-hydroxylase 1449227_at −2.63
Cyp51 Cytochrome P450, family 51 1450646_at −2.62
1422533_at −2.34
Dbi Diazepam binding inhibitor 1433991_x_at +2.10
1455976_x_at +2.04
Dhcr24 24-dehydrocholesterol
reductase
1418129_at −2.94
1451895_a_at −2.97
Extl2 Exostoses (multiple)-like 2 1422538_at −3.38
1422539_at −2.39
Fads6 Fatty acid desaturase
domain family, member 6
1443904_at −2.14
Far1 Fatty acyl CoA reductase 1 1435315_s_at −2.41
Hmgcs1 3-hydroxy-3-methylglutaryl-
Coenzyme A synthase
1
1433444_at −3.4
1433445_x_at −3.11
1433446_at −2.45
Hsd11b1 Hydroxysteroid 11-beta
dehydrogenase 1,
1449038_at −2.32 −5.05
Hsd17b7 Hydroxysteroid (17-beta)
dehydrogenase 7
1457248_x_at −2.05 −2.88
Insig1 Insulin induced gene 1 1454671_at −2.14
Insig2 Insulin induced gene 2 1417980_a_at −2.58
1417981_at −2.58
Ldlr Low density lipoprotein
receptor
1421821_at −3.39
lpl Lipoprotein lipase 1431056_a_at +5.99 −11.21
Lrp11 Low density lipoprotein
receptor-related protein 11
1433536_at −3.96
(Continued)
TABLE 4 | Continued
Gene Full name Affymetrix Symptomatic Late-stage
probeset ID FC FC
Lrp12 Low density
lipoprotein-related protein
12
1433864_at −2.28
Lypd6b LY6/PLAUR domain
containing 6B
1429274_at −2.84
Nsdhl NAD(P) dependent steroid
dehydrogenase-like
1416222_at −2.96
Nus1 Nuclear undecaprenyl
pyrophosphate synthase 1
homolog (S. cerevisiae)
1419914_s_at −2.01
Osbpl1a Oxysterol binding
protein-like 1A
1460192_at −2.69
Osbpl6 Oxysterol binding
protein-like 6
1457881_at −3.19
Osbpl8 Oxysterol binding
protein-like 8
1437069_at −2.17
Sc4mol Sterol-C4-methyl
oxidase-like
1423078_a_at −2.97
Sc5d Sterol-C5-desaturase
(fungal ERG3,
delta-5-desaturase)
homolog (S. cerevisae)
1434520_at −3.33
Scd1 Stearoyl-Coenzyme A
desaturase 1
1415964_at −2.43
Sqle Squalene epoxidase 1415993_at −3.09
Stard4 StAR-related lipid transfer
(START) domain containing
4
1429240_at −2.93
1455011_at
Tspo Translocator protein 1438948_x_at +2.04
response beginning at symptomatic and continuing through to
the late-stage of disease, shown by the large overlap of increased
transcripts between these two stages (Figure 4). Whilst there
is evidence of neuronal and microglial contamination in the
LCM samples (Supplementary Figure 1), it is well established
that astrocytes are highly activated during the late-stages of
disease. In addition, our experiments, particularly those looking
at the phagocytosis of neuronal debris and cholesterol synthesis,
sought to confirm these as astrocytic phenomena by using
pure cultures of astrocytes. The lysosomal up-regulation seen
at the symptomatic time-point, with further up-regulation at
late-stage, would be in keeping with either: attempts to deal
with intracellular inclusions, and/or increased phagocytosis of
motor neuronal debris. At the late-stage time-point, defects in
ion homeostasis and cholesterol and steroid metabolism are
also seen. The greatly increased expression of genes involved
in immune function, complement, cell signaling, and secretion
pathways seen at the symptomatic time-point are less apparent at
late-stage, which probably reflects the widespread dysregulation
of transcripts in astrocytes at this time-point leading to a lower
enrichment. It is apparent from these data that a transition
occurs between the pre-symptomatic and symptomatic time-
points leading to a reactive astrocyte phenotype characterized
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FIGURE 3 | (A) Transcripts involved in intracellular cholesterol synthesis and transport are dysregulated in late-stage SOD1G93A astrocytes vs. NTg controls. Blue
indicates decreased expression, red indicates increased expression, number indicates fold-change vs. NTg control. (B) Intracellular cholesterol levels in neonatal
SOD1G93A astrocytes are significantly lower than those in NTg controls. (C) Simplified schematic of SREBP2 regulation. Excess cholesterol or lanosterol inhibits
SCAP-mediated transport of SREBP2 to the golgi apparatus. Consequently, SREBP2 is not activated and does not translocate to the nucleus to upregulate
cholesterol synthesis and genes such as Insig1 and Ldlr which are decreased in late-stage SOD1G93A astrocytes. (D) SREBP2 staining in the ventral horn of NTg (left)
and SOD1G93A (right) lumbar spinal cord of late-stage mice, top panels indicate 20X magnification and bottom panels 40X magnification. In NTg spinal cord,
negatively stained areas show the morphology of motor neurons (dotted lines) whereas in SOD1G93A spinal cord cells with motor neuron morphology stain positively
for SREBP2 in the cytoplasm (arrow). In addition SREBP2 appears to be located in long processes which may belong to astrocytes or neurons (arrowhead). Scale
bars = 100µm. ****p ≤ 0.0001.
by increased chemokine secretion, lysosomal up-regulation and
up-regulation of stress response factors which carries through to
late-stage. This is reinforced by a recent gene expression
study of SOD1G93A spinal cord which reported an increase
in antigen presentation transcripts from an early pre-
symptomatic stage (40d) to a late-pre-symptomatic stage
(80d) (de Oliveira et al., 2013). For maximum applicability of
functional data to both disease stages, we chose to functionally
investigate this reactive response rather than the down-
regulation of categories such as ion homeostasis due to the
aforementioned large overlap for up-regulated transcripts
(Figure 4).
The increase in expression of cathepsin transcripts is in
keeping with several previous studies which reported increased
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FIGURE 4 | Venn diagram of the (A) up-regulated and (B) down-regulated genes that are differentially expressed in SOD1G93A astrocytes at
pre-symptomatic, symptomatic, and late-stage disease. The greatest overlap occurs between up-regulated transcripts in symptomatic and late-stage
SOD1G93A astrocytes. In comparison very few genes are shared between pre-symptomatic astrocytes and the other two disease stages, or between all three disease
stages together.
expression in glia (Fukada et al., 2007) and decreased expression
in motor neurons in SOD1-ALS (Wootz et al., 2006; Cox
et al., 2010; Kirby et al., 2011), suggesting up-regulation of
the lysosomal pathway is astrocyte-specific. Up-regulation of
lysosomal proteins could be as a result of increased amounts
of autophagy of SOD1G93A protein, aggregates of which
are degraded by autophagy in vitro (Kabuta et al., 2006).
Interestingly, SOD1 and CtsD are co-localized in motor neurons
of sALS patients (Forsberg et al., 2010). However, our results do
not show an up-regulation of the classic autophagy related genes
such as Beclin 1, Lc3-II, Vps34, or the Atg group of genes (Virgin
and Levine, 2009). This suggests that if autophagy is increased,
it is due to altered autophagic flux rather than induction of
autophagic genes.
Rather than a lysosomal up-regulation due to increased
autophagy, the microarray data suggests that lysosomal up-
regulation could be as a consequence of increased astrocyte
phagocytosis (Table 1). Indeed, in addition to the cathepsin
group of proteases, this study is the first to highlight an increased
β-hexosaminidase activity in SOD1G93A spinal cord at the late-
stage of disease (Figure 1B). The fact that both transcripts that
make up the two β-hexosaminidase isoforms are differentially
expressed in themicroarray datamakes it highly likely that part of
this increased activity comes from astrocytes. β-hexosaminidase
is involved in the processing of gangliosides, which are abundant
upon cell membranes, and its increased activity from the
symptomatic stage onwards may be in response to increased
processing of neuronal debris. Astrocytes are capable phagocytes
(Chang et al., 2000) and their phagocytosis of cell debris is
seen to protect neurons from contact-induced cell death in vitro
(Lööv et al., 2012). Here we compared the phagocytic ability of
SOD1G93A astrocytes vs. NTg controls and have shown for the
first time that SOD1G93A astrocytes have an increased propensity
to phagocytose cellular debris (Figure 2). Again, the results of the
functional study were consistent with the up-regulation of several
membrane receptors for phagocytosis (Table 2). Given the data
of Lööv et al. (2012), we hypothesize that this would actually
function as a protective mechanism during the disease course
and dampen inflammation. In support of this, macrophage
phagocytosis of either apoptotic or necrotic debris does not affect
expression of pro-inflammatory cytokines (Brouckaert et al.,
2004).
Frontiers in Cellular Neuroscience | www.frontiersin.org 11 October 2015 | Volume 9 | Article 410
Baker et al. The changing astrocyte phenotype during ALS
FIGURE 5 | The changing phenotype of astrocytes during the disease
course in the SOD1G93A mouse. Italics indicate data inferred from
microarrays whilst non-italics indicate data for which functional outcomes have
been observed. At the pre-symptomatic stage astrocyte gene expression is
characterized by disruptions in lactate provision to neurons and mitochondrial
dysfunction, as well as perturbations in secreted trophic factors such as the
pro-NGF:NGF ratio. At the symptomatic time-point astrocytes take on a much
more reactive phenotype characterized by increased lysosomal, phagocytic
and chemokine gene expression whilst also featuring a down-regulation of
genes involved in potassium transport. At late-stage disease astrocytes feature
differential expression of a large number of genes, and still show the disruption
seen at the symptomatic stage. In addition cholesterol synthesis transcripts
are differentially expressed at this time-point which may indicate an excess of
cholesterol in the CNS, or a disruption in the activation of cholesterol synthesis.
At the late-stage of disease in particular, many transcripts
involved in cholesterol and steroid homeostasis are dysregulated
in SOD1G93A astrocytes. Astrocytes are important in the adult
CNS as they provide cholesterol and cholesterol precursors to
neurons via transport proteins such as APOE (Pfrieger and
Ungerer, 2011). Another mouse model which closely resembles
ALS, featuring a deletion of the hypoxia response element
of the vascular endothelial growth factor gene (VEGFδ/δ),
shows down-regulation of many of the transcripts seen
in the present study including: Ldlr, Stard4, Hsd17b7, and
Sqle (Brockington et al., 2010). In contrast to the results of
ourselves and Brockington et al. (2010) showing decreased
cholesterol synthesis, Ceramide 24 and sphingomyelin (classes
of membrane lipid) and cholesterol-16 and -18 are increased
in the spinal cord of ALS patients and in the lumbar spinal
cord of the pre-symptomatic SOD1G93A mouse (Cutler et al.,
2002). The decreased intracellular cholesterol measured in the
current study may be the reason for increased translocator
protein (Tspo) (120d: +2.04), which along with diazepam
binding inhibitor (Dbi) (120d: +2.4) induces translocation
across the mitochondrial membrane (Rone et al., 2009).
This may be an attempt by the cell to increase cholesterol
transport into mitochondria for steroid biosynthesis. However,
downstream steroid biosynthesis within mitochondria is
predicted to be decreased due to the decreased expression
of Hsd11b1 and Hsd17b7. This decreased expression is
superimposed upon the dysregulation of mitochondrial
transcripts already apparent in the pre-symptomatic SOD1G93A
astrocytes (Ferraiuolo et al., 2011a). Future therapeutic strategies
could focus upon mitochondrial protection to rescue this
deficit and thereby increase production of neuroprotective
steroids.
We show here that SOD1G93A astrocytes inherently produce
a lower amount of cholesterol than NTg controls. This is the
first time to our knowledge that this has been demonstrated.
The increased APOE activity seen in the microarray data might
therefore be an attempt to increase cholesterol transport in
response to lower astrocytic cholesterol synthesis. Future study
should focus upon confirming the increased expression of
APOE at the protein level. The increased staining of SREBP2
in motor neuronal cell bodies and process-like structures of
late-stage SOD1G93A lumbar spinal cord may result from a
neuronal reaction to lower cholesterol transport to neurons
from astrocytes, and an up-regulation of SREBP2 by neurons in
an attempt to synthesize cholesterol themselves. To investigate
this further, in vitro studies should be performed to investigate
whether increased extracellular cholesterol leads to cytoplasmic
SREBP2 localization in astrocytes or motor neurons and whether
the SOD1G93A mutation affects this.
This study has revealed three previously unexplored
phenomena in SOD1G93A astrocytes occurring at the
symptomatic stage and continuing to late-stage disease.
Intriguingly, these mechanisms may be interconnected and
future studies can now focus on characterizing these behaviors
further. Much focus is placed upon whether astrocytes become
toxic or lose supportive function during ALS progression. The
data presented in this report suggest that astrocytes react so
as to attempt damage limitation via clearance and processing
of cellular debris for re-distribution of components such as
cholesterol. In addition, the transcriptomic data of symptomatic
and late-stage SOD1G93A astrocytes show decreased expression
of many transcripts involved in ion homeostasis and transport,
suggesting that astrocytes are concurrently losing their ability
to regulate the external environment. Given this, we conclude
that the majority of behavior change in SOD1G93A astrocytes
during disease progression is a loss of supportive function rather
than a toxic gain of function and that this is equally damaging
to neuronal survival. It is important now to determine whether
these astrocytic behaviors can be modulated and whether this is
a means by which to influence disease progression.
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